1. What Happened?

On September 9, 2025, Legochem Bio signed a joint research and antibody technology licensing agreement with GO THERAPEUTICS for the development of new antibody-drug conjugates (ADCs). Through this agreement, Legochem Bio plans to develop new ADCs by incorporating GO THERAPEUTICS’ antibody technology. The agreement is conditional upon regulatory approval and can be terminated if research and development is discontinued or if product approval fails. The financial details of the agreement were not disclosed.

2. Why Does It Matter?

This agreement holds significant implications for strengthening and expanding Legochem Bio’s ADC pipeline. The introduction of new antibody technology can complement the existing pipeline and increase the possibility of developing new ADCs. Furthermore, the collaboration with a US biotech company serves as an opportunity to demonstrate Legochem Bio’s technological prowess in the global market and increases the potential for future licensing and commercialization.

3. So What?

  • Positive Outlook: Successful joint research may lead to the development of new ADC candidates, securing additional milestone and royalty revenue, and strengthening global market competitiveness.
  • Potential Risks: The inherent uncertainties of clinical development, the difficulty in assessing the value due to non-disclosure of the agreement amount, and the volatility of the KRW/USD exchange rate should be considered.

4. What Should Investors Do?

This agreement is a positive factor that supports Legochem Bio’s long-term growth potential. However, due to uncertainties such as the progress of clinical development and regulatory approvals, a cautious approach is necessary when making investment decisions. It is crucial to closely monitor future disclosures and market conditions while formulating an investment strategy.